The POPular AGE randomized controlled trial found no benefit of ticagrelor versus clopidogrel among patients aged 70 years or older with non-ST-elevation acute coronary syndrome (MACE in 11% vs 12% of patients) The ALPHEUS randomized controlled trial found no benefit of ticagrelor versus clopidogrel among stable coronary patients undergoing high-risk elective PCI (primary outcome in 35% vs 36% of patients). Īre non-thienopyridines agents better than thienopyridine (second-generation) agents? Studies of all patients The TRILOGY ACS randomized controlled trial found no benefit of prasugrel versus clopidogrel (primary outcome: 13.9% vs 16% hazard ratio 0.91 0.79 to 1.05 P=0.21) among "patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization".
0 Comments
Leave a Reply. |